Orion and Alligator Bioscience amend their agreement concerning two bispecific antibodies
November 19 2024 - 11:30AM
UK Regulatory
Orion and Alligator Bioscience amend their agreement concerning two
bispecific antibodies
ORION CORPORATION
INVESTOR NEWS
19 NOVEMBER 2024 at 18.30 EET
Orion and Alligator Bioscience amend their agreement
concerning two bispecific antibodies
Orion Corporation and Alligator Bioscience AB have agreed on the
conversion of the previously granted royalty-bearing license to
Orion Corporation to two bispecific antibodies that the companies
have been successfully developing in collaboration using
Alligator’s RUBY® bispecific format to a perpetual, fully
paid, royalty-free license. Orion will continue to develop these
antibodies, which are currently in late-stage pre-clinical
development, without any obligation to pay any milestone payments
or royalties to Alligator. In connection with the amendment of the
agreement, Orion pays Alligator a one-time payment of EUR 3.5
million.
Contact person:
Tuukka Hirvonen, Investor Relations, Orion Corporation
Tel. +358 10 426 2721
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
http://www.orion.fi/en
http://www.twitter.com/OrionCorpIR
Orion is a globally operating Finnish pharmaceutical company – a
builder of well-being for over a hundred years. We develop,
manufacture and market human and veterinary pharmaceuticals and
active pharmaceutical ingredients. Orion has an extensive portfolio
of proprietary and generic medicines and consumer health products.
The core therapy areas of our pharmaceutical R&D are oncology
and pain. Proprietary products developed by Orion are used to treat
cancer, neurological diseases and respiratory diseases, among
others. Orion's net sales in 2023 amounted to EUR 1,190 million and
the company had about 3,600 employees at the end of the year.
Orion's A and B shares are listed on Nasdaq Helsinki.
Orion (TG:OFK)
Historical Stock Chart
From Nov 2024 to Dec 2024
Orion (TG:OFK)
Historical Stock Chart
From Dec 2023 to Dec 2024